Cancer is the uncontrolled proliferation of certain cells in the body that, over time, drive out normal cells. Breast cancer can develop when cells in the breast begin to grow out of control. These cells usually form a tumor that feels like a lump and can be confirmed by a mammogram. If the cells in the tumor may expand into surrounding tissues or spread to other parts of the body, it is considered malignant. Breast cancer affects almost mostly women, while it can potentially affect men. Normal breast cells can become malignant as a result of DNA mutations. Some DNA alterations are passed down from parents and can increase the risk of breast cancer considerably.
According to the Breast Cancer Therapeutics Market, 252,710 new instances of breast cancer are predicted to be diagnosed in the United States in 2017, with 63,410 cases being non-invasive breast cancer. Breast cancer fatality rates in the United States are greater than any other cancer in women, with the exception of lung cancer. Breast cancer is more common in women under the age of 45 and African American women than in white women.
The market for breast cancer therapies will expand as the disease becomes more common, especially in developed countries.
Breast cancer is the second most frequent type of cancer worldwide (lung cancer is the first), and the most common type among women, according to World Health Organization figures. This form of cancer affects 20% of all invasive cancers in women and 13% of all female cancers, and it is responsible for 15% of all cancer-related fatalities worldwide, including females and males. Every year, roughly 200,000 new cases in women and 2,000 new cases in men are diagnosed.
Important Developments
The market for breast cancer therapies will expand as the disease becomes more common, especially in developed countries.
Breast cancer is the second most frequent type of cancer worldwide (lung cancer is the first), and the most common type among women, according to World Health Organization figures. This form of cancer affects 20% of all invasive cancers in women and 13% of all female cancers, and it is responsible for 15% of all cancer-related fatalities worldwide, including females and males. Every year, roughly 200,000 new cases in women and 2,000 new cases in men are diagnosed.
Important Developments
In order to get a competitive edge in the Breast Cancer Therapeutics Market, key market players engage in various business tactics such as research and development. In July 2019, for example, Eli Lilly and Firm, a pharmaceutical company based in the United States, announced positive findings for Verzenio (abemaciclib), which showed a significant improvement in overall survival in Phase 3 MONARCH 2 clinical study. Verzenio is a drug that can be used to treat advanced or metastatic breast cancer.
In order to expand their product portfolio and enhance the Breast Cancer Therapeutics Market position, key market players are pursuing various growth strategies, such as obtaining regulatory approval for new products. For example, Eisai Co., Ltd., a Japanese pharmaceutical company, gained New Drug Approval for Halaven, an anticancer drug, in July 2019.
In order to expand their product portfolio and enhance the Breast Cancer Therapeutics Market position, key market players are pursuing various growth strategies, such as obtaining regulatory approval for new products. For example, Eisai Co., Ltd., a Japanese pharmaceutical company, gained New Drug Approval for Halaven, an anticancer drug, in July 2019.
0 Comments